Research Project: Evaluating the effectiveness of ferrous bisglycinate (IronUp®) in reversing iron deficiency in pregnant women
In a collaborative research study between the Max Biocare Institute and Mahidol University in Thailand, doctors and researchers are conducting a randomised controlled trial to evaluate and compare the effectiveness of two different iron forms, ferrous bisglycinate in IronUp® (24mg iron) versus ferrous fumarate (66mg iron), in reversing iron deficiency in pregnant women in Thailand.
IronUp® is a TGA listed formulation containing Ferrochel®, a patented chelated form of iron. Scientific research has shown iron in the chelated form has greater bioavailability compared to iron in a salt form (i.e. ferrous fumarate). This means it is more efficiently absorbed, hence, a smaller dosage can be administered. In addition, chelated iron is associated with less gastrointestinal side effects than iron salts. Another feature of IronUp® is it contains additional nutrients including vitamin C, folic acid (vitamin B9), folinic acid and B-group vitamins (B1, B2, B6 and B12).
A total of 120 pregnant women with iron deficiency will be divided into 2 groups, and each group will be administered one treatment for 6 consecutive months, either IronUp® (1 capsule daily) or ferrous fumarate (1 tablet daily). Parameters such as haematological status, iron absorption, side effects, quality of life and general wellbeing will be monitored during and after the trial to analyse treatment effectiveness in reversing iron deficiency in pregnant women.
This study is registered with the Thai Clinical Trials Register and we have finished recruiting participants for this trial.